Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's DiseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers tested whether curcumin, at three doses (40, 80, 160 mg/kg), could improve motor impairment, dopamine neuron loss, and gut microbiota disruption in the MPTP mouse model of Parkinson's disease.
How was it studied?
Six groups of mice (control, solvent control, MPTP, and three curcumin doses) underwent pole, hanging, and open-field tests after 14 days. Tyrosine hydroxylase immunohistochemistry and electron microscopy assessed dopamine neuron survival and ultrastructure, and 16S rRNA sequencing profiled gut microbiota.
What did they find?
All curcumin doses reduced pole-climbing time and increased suspension scores and movement distance dose-dependently, with better dopamine neuron survival and less cell degeneration at higher doses. The MPTP group showed higher relative abundance of Patescibacteria, Proteobacteria, and Verrucomicrobia, while Patescibacteria, Enterobacteriaceae, and Enterococcaceae abundance decreased in all curcumin groups. Medium and high curcumin doses also reduced a KEGG pathway for N-acetylneuraminate degradation.
Why it matters
This preliminary mouse study suggests curcumin may offer neuroprotective benefits in Parkinson's disease partly through modulating gut microbiota composition, supporting further research into microbially targeted therapies.